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Abstract
One of the control mechanisms of cathepsin B biosyn-
thesis and trafficking operates through alternative splic-
ing of pre-mRNA. An mRNA lacking exon 2 is more
efficiently translated than that containing all exons, and
may be responsible for elevated biosynthesis and
enzyme routing to the extracellular space, with critical
consequences for connective tissue integrity in patholo-
gies such as cancer and arthritis. mRNA missing exons
2 and 3 encodes a truncated procathepsin B form that
is targeted to mitochondria. This enzyme variant is cat-
alytically inactive because it cannot properly fold. How-
ever, it provokes a cascade of events, which result first
in morphological changes in intracellular organelles and
the nucleus, finally leading to cell death.
Keywords: cysteine peptidases; mitochondria;
overexpression; trafficking; unfolded protein;
untranslated region.
Introduction
Cathepsin B, a cysteine peptidase of the papain family
(EC 3.4.22.1, identifier C01.060 in the Merops database;
Rawlings et al., 2004), has been typically classified as a
lysosomal enzyme. However, it is also responsible for a
variety of extracellular functions, is found at cell surfaces,
and a truncated form is targeted to mitochondria. Some
of these extralysosomal properties of cathepsin B are
due to altered expression at the gene level, as well as to
enzyme overproduction and/or atypical trafficking. Nor-
mal and abnormal expression can be regulated by tran-
scriptional efficiency, by different transcription starting
points (Gong et al., 1993; Berquin et al., 1995), by the
use of alternative promoters (Yan and Sloane, 2003), and
by variable pre-mRNA splicing (Gong et al., 1993; Berardi
et al., 2001; Zwicky et al., 2002, 2003; Mu¨ntener et al.,
2003, 2004).
During the splicing of eukaryotic precursor mRNAs, the
introns are removed and the exons are joined together.
Alternative mRNA splicing is a frequent event that occurs
in a cell-specific or developmental-specific manner in
approximately 60% of all human gene products (Modrek
and Lee, 2002). It involves the combination of different
splice junctions that give rise to functionally distinct pro-
teins, allowing a gene to multiply its coding capacity and
thereby to synthesize a number of structurally and func-
tionally distinct protein forms far exceeding the number
predicted by the genome. In this article we review our
contribution to the study of alternative splicing of human
cathepsin B pre-mRNA, with emphasis on the untrans-
lated regions (UTR), and discuss the consequences of
this event for protein synthesis, trafficking and function.
The cathepsin B gene, its transcripts and
protein products
The human cathepsin B gene, located on the short arm
of the 8p22 region of chromosome 8 (Fong et al., 1986;
Wang et al., 1988), contains 13 exons (12 exons plus
exons 2a,b) and has a coding portion of only approxi-
mately 1 kb, although its total length is at least 27 kb
(Figure 1). Exons 2a,b (119 bp) have been discovered in
cells from a human gastric adenocarcinoma (Berquin et
al., 1995). Three cathepsin B transcripts, alternatively
spliced in the 59-region and relevant to this review, are
shown in Figure 2. The standard 39-UTR of cathepsin B
mRNA contains the complete exon 11, giving rise to a
2.2-kb RNA, while a 4-kb variant contains 141 nucleo-
tides of exon 11 and the complete exon 12 (Gong et al.,
1993). Another 1.7-kb transcript results from splicing of
the coding region to a more downstream portion of the
39-UTR (Tam et al., 1994). The presence or absence of a
10-bp sequence in the 39-UTR is crucial for stabilization
of the transcripts through a stem loop (Tam et al., 1994).
As the regular start codon is located in exon 3, the full-
length transcript, CB(full), and the transcript lacking exon
2, CB(-2), code for the same protein, namely preproca-
thepsin B. This consists of a 17-aa-long signal peptide,
followed by an inhibitory propeptide of 62 aa, the single-
chain enzyme (254 aa), and a C-terminal propeptide
of 6 aa. The protein is directed to the endoplasmic retic-
ulum by the signal peptide, which is then removed and
the protein becomes glycosylated at two sites, one in the
propeptide and one in the mature protein region. The
mannose-6-phosphate recognition marker, added to
the propeptide in the Golgi apparatus, conveys the
enzyme to the endosomes, where the mature single-
chain form of 27.8 kDa is generated by removal of the
propeptide through limited proteolysis. Further process-
ing occurs in the endosomal-lysosomal compartment,
where the C-terminal hexapeptide and two internal amino
acids are trimmed off, and the N-linked oligosaccharide
of the heavy chain is degraded to the level of a single
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Figure 1 The human cathepsin B gene.
This scheme was generated using nucleotides 11760450–
11791965 (in reverse order) of the chromosome 8 sequence of
the Homo sapiens genome (build 30) as provided on
www.ncbi.nlm.nih.gov and the pDraw32 software. The location
of exon 2a/b was determined using the published sequence
(Berquin et al., 1995). The boundaries of all other exons (shown
by numbers) were determined using the published exon-intron
junction sequences (Gong et al., 1993). Exon 1, 124 bp (59-UTR);
exon 2, 88 bp (59-UTR); exon 2a/b, 119 bp (59-UTR); exon 3,
151 bp (consisting of a 25-bp 59-UTR and 126-bp coding region);
exon 4, 86 bp; exon 5, 115 bp; exon 6, 119 bp; exon 7, 86 bp;
exon 8, 144 bp; exon 9, 117 bp; exon 10, 129 bp; exon 11,
896 bp (consisting of a 98-bp coding region and 798-bp 39-UTR);
exon 12, ca. 2700 bp. The restriction sites are also shown.
Figure 2 Alternative cathepsin B messages in the 59 region and
their protein products.
Exons are drawn to scale. Here only the standard 39-UTR is
shown, which contains the complete exon 11. An alternative 39-
UTR contains 141 nucleotides of exon 11 and the complete exon
12. Black, 59-UTR; hatched, 39-UTR; white, coding region.
N-acetylglucosamine residue. The mature lysosomal
enzyme consists of a heavy and a light chain of 22.4 and
5.2 kDa, respectively, joined by a disulfide bridge
(reviewed by Mort, 2004).
Translational efficiency
The question arises as to whether there is any special
reason to be interested in the 59-UTR variants CB(full) and
CB(-2) if they encode the same protein. The answer is
yes, especially as the 88-nt-long exon 2, which is part of
an Alu element (Berquin et al., 1997), regulates the trans-
lational efficiency of the transcripts. To quantitatively
measure this property, and in parallel the role of the 39-
UTR, we used constructs containing cathepsin B ele-
ments fused to the coding sequences of the green
fluorescent protein or luciferase (Zwicky et al., 2003). We
analyzed the expression of the alternative transcripts as
functional proteins by quantitative confocal fluorescence
microscopy in living cells and by luminescence analysis
using four mammalian cell lines: T/C-28a2 immortalized
chondrocytes, HeLa, CHO-K1 and COS-1 cells. As a
general trend, constructs missing exon 2 were biosyn-
thetically more efficient than the full-length counterpart in
all cell types. Cloning the luciferase reporter upstream of
the 39-UTR, downstream of the 59-UTR, or in between the
59- and 39-UTR enabled us to analyze the impact of the
UTRs on cathepsin B expression. These UTRs downre-
gulated luciferase biosynthesis moderately when present
individually, with the 39-UTR being more efficient than the
59-UTR, but downregulated it even more when present
simultaneously. Since these measurements only consid-
ered the effect of parts of the 59-UTR of cathepsin B
mRNA in expressing reporter proteins, and might thus
be considered somewhat artificial, we addressed the
question of the translational efficiency of the CB(full) and
CB(-2) transcripts using antisense methods. We de-
signed an antisense nucleotide consisting of 24 bases
specifically designed to hybridize with CB(-2) by binding
12 bases each on exon 1 and exon 3, and considered
the appropriate controls (Zwicky et al., 2002). Application
of this antisense oligonucleotide to a human immortal-
ized chondrocyte cell line, T/C-28a2, the mRNA of which
contained only 6% of the CB(-2) splice variant, showed
that this transcript was responsible for 30–50% of the
total biosynthetic activity. Considering these results and
the outcome for the reporter proteins described above,
we conclude that the translational efficiency of CB(-2)
can range between two- and 15-fold higher than that of
CB(full), depending on the conditions and the particular
cell.
The transcript lacking both exons 2 and 3, CB(-2,3),
can be translated because of a second in-frame start
codon present in exon 4 (Figure 2). However, this tran-
script leads to a truncated form of procathepsin B that
lacks the signal peptide (necessary for import into the
endoplasmic reticulum) and 34 residues of the inhibitory
propeptide. Using fusion constructs containing green flu-
orescent protein and luciferase to monitor protein bio-
synthesis, the translational efficiency of CB(-2,3) was
shown to be maximally 4.5-fold higher than that of
CB(full), depending on the cells (Zwicky et al., 2003).
Occurrence of alternative cathepsin B
transcripts in cells and tissues
There are only a few reports on the occurrence of alter-
natively spliced cathepsin B transcripts in human tissues
(Gong et al., 1993; Berquin et al., 1995; Lemaire et al.,
1997; Hizel et al., 1998; Berardi et al., 2001). The CB(full)
and CB(-2) transcripts are found in variable proportions
in normal and pathological tissues, with a trend to over-
expression of CB(-2) in tumors (Gong et al., 1993; Hizel
et al., 1998). The CB(-2,3) variant, originally presumed to
be a rare tumor species (Gong et al., 1993), is also found
in normal and rheumatoid synovial tissue (Lemaire et al.,
1997), as well as in normal and osteoarthritic cartilage
(Berardi et al., 2001). The relative proportions of CB(full),
CB(-2) and CB(-2,3) in normal and osteoarthritic carti-
lages vary from specimen to specimen, but there is a
trend to an increase in the amount of CB(-2) and CB
(-2,3) in pathological tissues (Berardi et al., 2001) com-
pared to normal tissues. However, such statistical con-
siderations, which refer to bulk quantitative analyses in
the cartilage of a whole joint, do not make much sense.
In fact, in situ investigation by RT-PCR, aimed at mapping
the occurrence of the three transcripts through the depth
Cathepsin B regulation by alternative mRNA splicing 1019
Article in press - uncorrected proof
Figure 3 Human truncated procathepsin B in mitochondria.
(Left) A cathepsin B-green fluorescent protein chimera contain-
ing the first 65 amino acids of truncated procathepsin B starting
with position 52 (aa numbering of preprocathepsin B) was
induced in HeLa cells. Confocal fluorescence microscopy shows
in red metabolically active mitochondria stained with Mito-
Tracker red and in green the cathepsin B chimera. The yellow
color indicates co-localization of the red and green signals.
(Right) The N-terminal segment of human truncated procathep-
sin B showing a typical mitochondrial import motif, which con-
sists of an amphipathic a-helix with a positively charged patch
(red) opposite to a hydrophobic patch (green).
of articular cartilage from the surface down the subchon-
dral bone, revealed remarkable differences in their distri-
bution. While all transcripts were preferentially found in
the vicinity of the articular surface in normal cartilage,
they were distributed through the depth of the tissue in
osteoarthritic cartilage, with evident accumulation at
‘more involved’ sites (Berardi et al., 2001). This finding
agrees with independent localization results for cathe-
psin B activity by enzyme histochemistry (Baici et al.,
1995a,b).
Besides variations in the relative proportions of the 59-
UTR alternatively spliced transcripts, a trend towards
general enhancement of cathepsin B mRNA levels is
observed in pathological tissues compared to normal
counterparts (Berardi et al., 2001; Yan and Sloane, 2003).
Under homeostatic conditions, the total level of cathep-
sin B mRNA results in enzyme expression and trafficking,
which is efficiently controlled. Considering an increase in
both the total mRNA level and in the proportion of the
splice variant CB(-2), a quiet housekeeping function can
be ascribed to the CB(full) message, while CB(-2)
appears to be responsible for uncontrolled enzyme over-
production and misrouted trafficking.
Trafficking
Transient transfection experiments with cathepsin B con-
structs fused to the green fluorescent protein were
performed in human immortalized chondrocytes and
HeLa cells. Co-localization with the trans-Golgi network
and the acidic compartment was monitored using spe-
cific markers. As expected, the product of CB(full) and
CB(-2) appeared in the trans-Golgi network and from
there it was delivered to the endosomal-lysosomal com-
partment as its final location (Mu¨ntener et al., 2003).
Inclusion or omission of the 6-aa-long C-terminal pro-
peptide had no influence on cathepsin B trafficking.
Mutation of the glycosylation site Asn 38 to Gln pre-
vented the necessary glycosylation for targeting the nas-
cent protein to the lumen of the endoplasmic reticulum,
and the product of this construct was first detected in
the rough endoplasmic reticulum before being directly
delivered to the secretory pathway. However, in contrast
to breast carcinoma cells (Moin et al., 2000), we could
not confirm the existence of an alternative, mannose-6-
phosphate receptor-independent delivery path to the
acidic compartment in chondrocytes and HeLa cells.
There is indeed a difference between our approach and
that of Moin et al. in including (Mu¨ntener et al., 2003) or
not including (Moin et al., 2000) elements of the 59-UTR
in the constructs with green fluorescent protein.
After transient transfection of cells with the constructs
CB(full) and CB(-2) as just described, regular targeting of
procathepsin B to endosomes and lysosomes was evi-
dent, and we also observed its extracellular release.
Secretion was enhanced in the case of overexpression
and was particularly evident with constructs lacking exon
2 from the 59-UTR. This property correlates with the
known secretion of procathepsin B in cases of overex-
pression, as documented, for instance, in tumors (Frosch
et al., 1999) and osteoarthritis (Berardi et al., 2001). In
addition to observing procathepsin B secretion from
osteoarthritic and dedifferentiated chondrocytes in cul-
ture, we could extract intact glycosylated procathepsin B
from human osteoarthritic cartilage (Berardi et al., 2001).
We have demonstrated that procathepsin B accumulates
in pathological cartilages by binding to the extracellular
matrix, and that proenzyme contact with sulfated glycos-
aminoglycans promotes its conversion to the active form,
which can be detected using a specific enzyme histo-
chemical assay (Baici et al., 1995b).
Without knowing further details, it could be supposed
that truncated procathepsin B, the product of the splice
variant CB(-2,3), is rapidly eliminated after biosynthesis
because it cannot be conveyed to the endoplasmic retic-
ulum, modified in the Golgi apparatus or sent to the lyso-
somal or to the secretory pathway. Early in vitro results
that reported the artificial expression of truncated pro-
cathepsin B in COS cells and folding into an active
enzyme (Mehtani et al., 1998) could not be confirmed by
our recent studies (Mu¨ntener et al., 2005). After observing
a cytoplasmic and structured localization of green fluo-
rescent protein following transfection of chondrocytes
and HeLa cells with a cathepsin B construct missing
exons 2 and 3 fused to green fluorescent protein (Mu¨n-
tener et al., 2003), a detailed study allowed us to track
the final destination of truncated procathepsin B to a pre-
viously unsuspected location, the mitochondrion (Mu¨n-
tener et al., 2004). Co-localization of the truncated
procathepsin B-green fluorescent chimeras with mito-
chondria was demonstrated by specifically labeling these
organelles with MitoTracker red, which fluoresces red in
metabolically active mitochondria (Figure 3, left).
How truncated procathepsin B enters
mitochondria and the consequences
Close examination of the N-terminal sequence of trun-
cated procathepsin B, which starts with Met 52, reveals
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the presence of a typical leader sequence for the import
of proteins into the mitochondrial matrix (Chacinska et
al., 2002). This consists of a small patch of hydrophobic
amino acids, opposite to a patch of positively charged
amino acids in an amphipathic a-helix, as shown in Fig-
ure 3 (right). This Figure was drawn from the published
structure of procathepsin B (Turk et al., 1996) by deleting
amino acids up to position 51 and showing 15 residues,
starting at position 52. Only the side chains of the resi-
dues that make up the helix are explicitly represented.
The propensity of this segment of the molecule to form
an amphipathic helix in truncated procathepsin B was
confirmed by computation using the program PSIPRED
(McGuffin et al., 2000). Besides the co-localization exper-
iments described above and illustrated in Figure 3, we
directly verified the presence of truncated procathepsin
B inside mitochondria after isolation of subcellular parti-
cles of transfected HeLa cells by differential centrifuga-
tion, followed by Western blot analysis. Further evidence
that truncated procathepsin B is delivered to the mito-
chondrial matrix comes from the presence, in Western
blots, of two bands shortened by 2.5- and 4.4-kDa pep-
tides with respect to the molecular mass of the chimera
(Mu¨ntener et al., 2004). It is strongly suspected that such
shortening is due to the action of mitochondrial process-
ing peptidase, the enzyme responsible for cleaving off
the import presequences of proteins targeted to the mito-
chondrial matrix. This enzyme preferentially catalyzes
cleavage at positions having an arginine as the penulti-
mate residue (-2) with an aromatic side-chain at the next
position (q1) (Chacinska et al., 2002; Braun and Schmitz,
2004). There are two such potential cleavage sites in the
N-terminal segment of truncated procathepsin B, namely
between aa 73–74 and 89–90 (preprocathepsin B
numbering).
Inside the mitochondrion, instead of behaving as an
innocent bystander, truncated procathepsin B has dele-
terious consequences for cell integrity. Morphological
alterations are observed in the trans-Golgi network, in the
acidic compartment, in mitochondria and, most promi-
nently, in the nucleus, which undergoes drastic defor-
mation followed by cell death (Mu¨ntener et al., 2003,
2004; Zwicky et al., 2003). Although such properties
might be attributed to proteolytic events on the part of
truncated procathepsin B, we demonstrated that this
enzyme form is catalytically inactive (Mu¨ntener et al.,
2005). The propeptide of cathepsin B exerts a double
function: as a chaperone it assists correct folding of the
nascent protein, and as an inhibitor it prevents substrate
binding by running its chain over the active center in a
direction opposite to that of a regular peptidic substrate.
We tested the capability of procathepsin B to fold and to
become enzymatically active by expressing protein vari-
ants lacking up to 22 amino acids at the N-terminus in
baculovirus-infected insect cells. The Asp11–Arg20 a-helix
(proenzyme numbering) is necessary for efficient inhibi-
tory activity of the propeptide. Trimming away this ele-
ment or additional amino acids abolishes inhibition.
Proenzyme variants, from which the N-terminal part
including the Trp24–Ala26 b-sheet is missing, or which
contain an amino acid mutation directly preceding this b-
sheet, are unable to fold (Mu¨ntener et al., 2005). There-
fore, procathepsin B forms lacking more than 22 amino
acids at the N-terminus would potentially be enzymati-
cally active, but they are destined to remain inactive
because they cannot fold correctly. Truncated procathe-
psin B, lacking 34 amino acids of the propeptide, has
thus no chance of folding and of becoming an active
enzyme.
A likely hypothesis to explain the deleterious effects of
truncated procathepsin B on cell integrity is the accu-
mulation of unfolded protein within the mitochondrial
matrix. Figure 3 clearly reveals the structure of mito-
chondria, organelles existing in two interconverting
forms: as small isolated, rounded particles (the typical
textbook image), and as extended filaments. These
extended mitochondria represent electrically connected
units, which facilitate energy delivery from the cell periph-
ery to the cell core. They function as intracellular power-
transmitting cables organized as a mitochondrial
reticulum (Skulachev, 2001). Careful analysis of confocal
images such as that shown in Figure 3 reveals changes
in the structure of the mitochondrial reticulum, and the
effects produced by the accumulation of unfolded trun-
cated procathepsin B can be visualized after dissecting
the co-localization features into the component colors
(Mu¨ntener et al., 2004). The physical integrity of mito-
chondria as a system of energy-delivering cables is
essential for their performance. We believe that accu-
mulation of unfolded truncated procathepsin B induces
the cell to physically fragment its mitochondrial reticulum
as a protective mechanism to prevent short circuit in the
whole electrical network. However, this reaction ultimate-
ly results in power failure and termination of energy deliv-
ery. The subsequent morphological changes reveal
features that resemble apoptosis rather than necrosis.
However, we cannot precisely assign them to a given
cell-death mechanism. They can possibly be placed
somewhere in one of the categories of cell death
described in a variety of physiological and pathological
situations, such as autophagy (Bro¨ker et al., 2005), onco-
sis (Otsuki et al., 2003) or paraptosis (Sperandio et al.,
2000). Unfortunately, a detailed study of the mechanism
of cell death induced by truncated cathepsin B is cur-
rently impossible, as this represents a process that
occurs slowly in an asynchronous way in only a few cells
at a time. The low frequency of this process might explain
the slow depletion of cells in tissues undergoing degen-
eration over many years, such as osteoarthritic cartilage.
In this pathological situation, characterized by overex-
pression of cathepsin B at both the mRNA and protein
level and with a clear presence of the CB(-2,3) mRNA
splice variant (Berardi et al., 2001), cell death is a rare
phenomenon, but this would be sufficient to deplete
articular cartilage of its cells in one or two decades.
Extending this concept, we can postulate a function of
truncated procathepsin B as a physiologically relevant
mechanism of cell death in tissues characterized by slow
turnover and populated by long-lived cells.
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